Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Australian Gonococcal Surveillance Programme annual report, 2015.

Monica M Lahra1,2, Rodney P Enriquez1,

  • 1Neisseria Reference Laboratory and World Health Organisation Collaborating Centre for STD, Sydney. Department of Microbiology, South Eastern Area Laboratory Services, The Prince of Wales Hospital, Randwick, New South Wales.

Communicable Diseases Intelligence Quarterly Report
|April 8, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Meningococcal B Vaccine to Prevent <i>Neisseria gonorrhoeae</i> Infection.

The New England journal of medicine·2026
Same author

False-positive <i>Neisseria gonorrhoeae</i> results on the Abbott Alinity m STI assay caused by <i>Neisseria meningitidis</i>: two cases from Australia.

Journal of clinical microbiology·2026
Same author

Limitations of Global Surveillance for Neisseria gonorrhoeae Antimicrobial Resistance.

Emerging infectious diseases·2026
Same author

Gene exchange between <i>Neisseria meningitidis</i> and <i>Neisseria gonorrhoeae</i>.

Microbial genomics·2026
Same author

Determining targets for ceftriaxone resistance detection in Neisseria gonorrhoeae based on genotype-phenotype data: an observational study.

The Lancet. Microbe·2025
Same author

Invasive Urogenital Neisseria meningitidis Serogroup Y Multilocus Sequence Type 1466.

Emerging infectious diseases·2025

The Australian Gonococcal Surveillance Programme (AGSP) tracked Neisseria gonorrhoeae antimicrobial resistance in 2015. Ceftriaxone resistance decreased, but azithromycin and penicillin resistance varied by region, with quinolone resistance high in South Australia.

Area of Science:

  • Microbiology
  • Public Health
  • Infectious Diseases

Background:

  • The Australian Gonococcal Surveillance Programme (AGSP) has monitored antimicrobial resistance in Neisseria gonorrhoeae since 1981.
  • Gonorrhoea treatment guidelines in Australia recommend dual therapy with ceftriaxone and azithromycin.

Observation:

  • In 2015, 5,411 clinical isolates were tested for antimicrobial susceptibility.
  • Decreased susceptibility to ceftriaxone was observed nationally (1.8%), a decrease from 5.4% in 2014.
  • High-level azithromycin resistance was reported in New South Wales and Western Australia.

Findings:

  • Penicillin resistance ranged from 8.7% in Tasmania to 33% in the Australian Capital Territory.
  • Quinolone resistance varied significantly, from 3.3% in remote Northern Territory to 41% in South Australia.

Related Experiment Videos

  • Azithromycin resistance rates ranged from 1.8% in Victoria to 5.8% in Queensland.

    • Implications:

    • Regional variations in antimicrobial resistance necessitate tailored treatment guidelines.
    • Continued surveillance is crucial for monitoring Neisseria gonorrhoeae resistance patterns.
    • Understanding resistance trends informs public health strategies to combat gonorrhoea.